Business Context and Reporting Period
This Form 8-K, dated January 3, 2019, reports a material definitive agreement entered into by Flex Pharma, Inc. ("Flex") and Salarius Pharmaceuticals, LLC ("Salarius"). The filing details an Agreement and Plan of Merger under which a Flex subsidiary will merge with Salarius, resulting in Salarius becoming a wholly-owned subsidiary of Flex. The transaction is structured as a reverse merger intended to qualify for tax-free treatment under Section 351(a) of the Internal Revenue Code.
Key Financial Metrics and Transaction Terms
- Valuation: Flex is valued at approximately $10.5 million (subject to adjustment based on net cash balance), and Salarius is valued at approximately $36.6 million (subject to adjustment based on Series A Unit sales).
- Ownership Structure: Upon closing, current Flex stockholders will own approximately 19.9% of the combined company, while current Salarius members will own approximately 80.1%.
- Consideration: Salarius units will convert into Flex Common Stock. Flex stockholders will receive a warrant to purchase Flex Common Stock exercisable six months and one day after closing.
- Warrant Terms: Warrants will have an exercise price equal to the fair market value on the closing date, be immediately exercisable upon receipt, and expire five years after receipt.
- Termination Fees: Flex may be required to pay Salarius a termination fee of $350,000 and/or reimburse expenses up to $200,000. Salarius may be required to pay Flex a termination fee of $350,000 or $1,000,000 depending on circumstances.
Material Changes and Corporate Actions
The filing does not report changes in historical revenue, profit, or cash flow, as this is a transaction announcement rather than a periodic financial report. However, the following material corporate changes are proposed:
- Reverse Stock Split: Flex intends to amend its certificate of incorporation to effect a reverse stock split to satisfy Nasdaq listing requirements.
- Name Change: Flex intends to change its corporate name to reflect the combined entity.
- Board Composition: The post-merger Board of Directors is expected to consist of seven members: six designated by Salarius and one by Flex.
- Voting Agreements: Key executives and directors holding approximately 35% of Salarius units and 0.5% of Flex stock have entered into voting agreements to support the merger.
Guidance, Risks, and Contingencies
Conditions to Closing: The merger is contingent upon several factors, including the effectiveness of a Form S-4 registration statement, approval by Salarius members and Flex stockholders, and listing on the Nasdaq Capital Market or Global Market.
Risks and Uncertainties: The filing highlights risks including the inability to complete the transaction, failure to obtain regulatory or stockholder approvals, potential litigation, and the possibility of a superior competing proposal. The combined company faces risks related to maintaining its management team and board.
Forward-Looking Statements: The document contains forward-looking statements regarding the transaction's completion and future operations, which are subject to significant risks and uncertainties. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the final net cash balance of Flex at closing to confirm the adjusted valuation of $10.5 million.
- Confirm the amount of Series A Units sold by Salarius to validate the $36.6 million valuation.
- Review the upcoming Form S-4 proxy statement/prospectus for detailed financial data and risk factors.
- Monitor the status of the reverse stock split and name change approvals by Flex stockholders.
- Check for any competing acquisition proposals that could trigger termination fees or alter the deal structure.